Our goal is to provide coating technology to effectively prevent hospital acquired infections from biofilm fouling of indwelling medical devices

Our CeraShield coated Biofilm-Resistant Endotracheal Tube, specifically designed to combat Ventilator-Associated Pneumonia (VAP), the most common, deadly HAI in ICU. VAP adds over Ten Billion Dollars in annual global treatment costs.

FDA Has Designated CeraShield Endotracheal Tube (ETT) As A “Breakthrough Device”. Cerashield ETT Is Cleared For Routine Clinical Use In Brazil, Canada, Colombia And UAE.


N8 Medical, LLC, a clinical-stage medical device company, is at the forefront of commercializing innovative medical devices enhanced with a novel class of active compounds known as Ceragenins.
N8 Medical’s goal is to revolutionize the safety of indwelling medical devices and implants. By applying our innovative CeraShield coating to these devices, we aim to prevent Hospital-Acquired Infections (HAIs), thereby reducing the reliance on antibiotics and combating Antimicrobial Resistance (AMR).

As an integral part of N8 Biosciences, a holding company committed to the extensive application of Ceragenins, N8 Biosciences is making strides in two key areas :


Ceragenins A Synthesis of Nature and Innovation


Our lead medical device is our CeraShield Endotracheal Tube which FDA has designated as a “breakthrough device” and is approved for routine clinical use in Canada, Colombia, Brazil and other ex US countries. We expect FDA approval in 2024.
The CeraShield ETT is designed to prevent Ventilator Associated Pneumonia (VAP) which is most common, deadly and costly HAI among ICU patients.
The estimated worldwide costs associated with treating VAP exceeds Ten Billion Dollars annually.









Endotracheal tube

Medical device, indwelling

Prevention of VAP / VARI

  Antimicrobial absorbable
Pacemaker envelope

Medical device, implant

Prevention of CIED infections

Coated pedicle screw

Medical device, implant

Prevention of implant-associated orthopedic infections



A recent published study by Professor Jordi Vila and his colleagues at the University of Barcelona, Spain has found that

Colistin is the last agent used to combat bacteria that are resistant to the strongest antibiotics. Colistin has remained the

A recent published study by Professor Robert Bucki and colleagues has shown that CSA-131 has broad spectrum antifungal activity and

Contact us

Lets Get in Touch!

Follow now


Basic contact form

N8 Medical, Inc. (N8 Medical) is a clinical-stage medical device company focused on commercializing medical devices that incorporate a novel class of active compounds called ceragenins.The subsidiaries for N8 Medical Inc are N8 Medical, LLC for Medical Device Development and Kinnear Pharmaceuticals, LLC for drug development.